There was no difference in the timing of randomization between the 2 groups. As we only considered events occurring between 3 and 12 months after the index procedure as primary end points, 65 patients were excluded from our analysis for various reasons before completion of the 3-month f...
Sole reliance on platelet function testing to determine the timing of surgery for patients on P2Y12 inhibitors should therefore be done with caution. 2014 Wiley Periodicals, Inc.doi:10.1111/jocs.12312Yu, Pey-JenCassiere, Hugh A.Dellis, Sophia L....
The timing of P2Y12i plus aspirin initiation is vital for balancing risks and benefits in patients with non-cardioembolic ischemic cerebrovascular events. Current guidelines suggest starting P2Y12i plus aspirin within 24 h of symptom onset for patients with minor non-cardioembolic IS who have not re...
Optimal timing to discontinue ticagrelor before cardiac surgery: do we need additional evidence? Eur J Cardiothorac Surg. 2019;55(4):720 1 https://doi.org/10.1093/ejcts/ezy420 Hansson EC, Malm CJ, Hesse C, Hornestam B, Dellborg M, Rexius H, et al. Platelet function recovery after ...
The major difference between the two trials was the timing of the administration of the study drugs. In the CHAMPION PCI trial, cangrelor or clopidogrel (600 mg) was started within 30 min before PCI. In the CHAMPION PLATFORM trial, cangrelor was started at the beginning of PCI, while ...
In another subanalysis of 18,761 patients (88.7% of the total PEGASUS–TIMI 54 population with a recorded history of the timing of their last P2Y12-receptor antagonist dose prior to randomization), results were reported for patients ≤30, >30 to 360, and >360 days from P2Y12-receptor anta...
This discrepancy may be related to the time between biomarker sampling, occurrence of the potential inflammatory trigger and timing of last drug dose, which was not captured in the PLATO trial. Currently, the potential effects of ticagrelor on mortality is being assessed in patients with pneumonia ...
P2Y12inhibitorprasugrelticagrelorGuidelines recommend treatment with a P2Y12 platelet adenosine diphosphate receptor inhibitor in patients undergoing elective or urgent percutaneous coronary intervention (PCI), but the optimal agent or timing of administration is still not clearly specified. The P2Y12 ...
The major difference between the two trials was the timing of the administration of the study drugs. In the CHAMPION PCI trial, cangrelor or clopidogrel (600 mg) was started within 30 min before PCI. In the CHAMPION PLATFORM trial, cangrelor was started at the beginning of PCI, while ...
Rapaport DH, Wong LL, Wood ED, Yasumura D, LaVail MM (2004) Timing and topography of cell genesis in the rat retina. J Comp Neurol 474:304–324. https://doi.org/10.1002/cne.20134 Article PubMed Google Scholar Moheimani F, Jackson DE (2012) P2Y12 receptor: platelet thrombus formati...